Results 11 to 20 of about 6,421 (186)

Risk of acute liver injury following the nirmatrelvir/ritonavir use [PDF]

, 2023
Background: Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were reported as adverse events of nirmatrelvir/ritonavir users in the EPIC-HR trial.Aim: To quantify the risk and severity of acute liver injury (ALI ...
Au, Ivan Chi Ho, Cheng, Wing Yiu, Cowling, Benjamin J, Lau, Eric Ho Yin, Lau, Kristy Tsz Kwan, Leung, Gabriel M, Mak, Lung Yi, So, Ching Hei, Wong, Carlos King Ho, Yuen, Man Fung   +9 more
core   +1 more source

High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients [PDF]

, 2023
Objectives: Immunocompromised patients have an increased risk of severe or prolonged COVID-19. Currently available drugs are registered to treat COVID-19 during the first 5 to 7 days after symptom onset.
Bogers, Susanne, Franken, Bas, Geurts van kessel, Corine H., Gharbharan, Arvind, Huygens, Sammy, Oude Munnink, Bas B., Rijnders, Bart J.A., Serroukh, Yasmina, Snoek, Britt, Van Hagen, P. Martin   +9 more
core   +2 more sources

MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY [PDF]

, 2023
Introduction: Molnupiravir and nirmatrelvir/ritonavir are antivirals used to prevent progression to severe SARS-CoV-2 infections, which reduce both hospitalization and mortality rates.
Adžić-Vukičević, Tatjana, Arellano, Elena, Bavastro, Martina, Besson, Caroline, Biernat, Monika M, Blennow, Ola, Buquicchio, Caterina, Calbacho, María, Cattaneo, Chiara, Cordoba, Raul, Cornely, Oliver A, Criscuolo, Mariana, Dargenio, Michelina, Del Principe, Maria Ilaria, Delia, Mario, Dávila-Valls, Julio, Erben, Nurettin, Espigado, Ildefonso, Falces-Romero, Iker, Farina, Francesca, Fouquet, Guillemette, Fracchiolla, Nicola S, García-Bordallo, Daniel, Gavriilaki, Eleni, Glenthøj, Andreas, Gräfe, Stefanie, Hernández-Rivas, José-Ángel, Hersby, Ditte Stampe, Itri, Federico, Koehler, Philipp, Kohn, Milena, Labrador, Jorge, Lavilla-Rubira, Esperanza, Limongelli, Alessandro, López-García, Alberto, Marchesi, Francesco, Marchetti, Monia, Martín-Pérez, Sonia, Meers, Stef, MelisÇOLAK, Gökçe, Merelli, Maria, Mitrovic, Mirjana, Mišković, Bojana, Mladenović, Miloš, Nordlander, Anna, Pagano, Livio, Pantic, Nikola, Petzer, Verena, Praet, Jens VAN, Prezioso, Lucia, Rahimli, Laman, Romano, Alessandra, Salmanton-García, Jon, Schönlein, Martin, Sili, Uluhan, Tascini, Carlo, Tragiannidis, Athanasios, Vena, Antonio, Weinbergerová, Barbora, Wolf, Dominik, Čolović, Natasa   +60 more
core   +3 more sources

Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients – a case series with four patients

BMC Nephrology, 2023
Background Despite vaccination coronavirus disease 2019 (COVID-19)-associated mortality caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains high in kidney transplant recipients.
Johanna Schneider, Rika Wobser, Wolfgang Kühn, Dirk Wagner, Yakup Tanriver, Gerd Walz   +5 more
doaj   +1 more source

NIRMATRELVIR/RITONAVIR (NIRI) EM PACIENTES COM COVID-19 E MALIGNIDADES HEMATOLÓGICAS: RELATO DO EPICOVIDEHA (REGISTRO INTERNACIONAL ONLINE DE PACIENTES COM MALIGNIDADES HEMATOLÓGICAS, INFECTADOS POR SARS-COV-2)

Brazilian Journal of Infectious Diseases, 2023
Introdução: O tratamento com NIRI diminui a taxa de hospitalização em pacientes imunocompetentes com COVID-19, mas os dados sobre a eficácia em pacientes com malignidade hematológica (MH) são escassos.
Jon Salmanton-García, Francesco Marchesi, Livio Pagano, Oliver A. Cornely   +3 more
doaj   +1 more source

Severe COVID-19 following Rituximab and Nirmatrelvir/ritonavir treatment in a patient with MCTD, Case Report [PDF]

, 2023
This is an article about how the use of medications such as nirmatrelvir/ritonavir can cause rebound COVID-19 and how the use of Rituximab, a biologic agent, can prolong the duration and increase severity of symptoms of COVID-19 in patients with pre ...
Baig, Rohail A, Chowdhury, Faieja, Dakwale, Pranjali, Mehta, Varun, Sheikh, Adnaan, Siddiqui, Omar   +5 more
core   +2 more sources

Simultaneous Determination of Nirmatrelvir and Ritonavir in Human Plasma by HPLC-MS/MS

Разработка и регистрация лекарственных средств, 2023
Introduction. SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2) is expected to remain a persistent global threat. Therefore, development of coronavirus disease 2019 (COVID-19) drugs is the most urgent global issue.
T. N. Komarov, P. K. Karnakova, O. A. Archakova, D. S. Shchelgacheva, N. S. Bagaeva, I. E. Shohin, K. Ya. Zaslavskaya, P. A. Bely   +7 more
doaj   +1 more source

Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge

Frontiers in Pharmacology, 2023
Background: Nirmatrelvir/ritonavir has demonstrated effectiveness in high-risk patients with coronavirus disease 2019 (COVID-19). However, investigations on the efficacy and safety of nirmatrelvir/ritonavir in patients with kidney dysfunction are limited.
Jiayi Yan, Jiayi Yan, Hong Cai, Jieying Wang, Mingli Zhu, Ping Li, Peiying Li, Bin Wu, Xiajing Che, Leyi Gu, Shan Mou, Shan Mou   +11 more
doaj   +1 more source

Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong [PDF]

, 2023
Importance: Diabetes and COVID-19 are both global pandemics, and type 2 diabetes is a common comorbidity in patients with acute COVID-19 and is proven to be a key determinant of COVID-19 prognosis.
Au, Ivan CH, Chung, Matthew SH, Cowling, Benjamin J, Lau, Eric HY, Lau, Kristy TK, Lee, Chi Ho, Lui, David TW, Wong, Carlos KH, Woo, Yu Cho   +8 more
core   +1 more source

Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in patients at high risk [PDF]

, 2023
Background Using a retrospective cohort study design, we aimed to evaluate the effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who were highly vulnerable. Methods The impact of each drug was determined via comparisons
Antoniadou, Anastasia, Filippou, Dimitrios, Gaga, Mina, Gerolymatos, Gerasimos, Gkolfinopoulou, Kassiani, Gkova, Maria, Kostaki, Evangelia-Georgia, Kotanidou, Anastasia, Loukides, Stylianos, Mellou, Kassiani, Mossialos, Elias, Paraskevis, Dimitrios, Psalida, Naya, Saroglou, Georgios, Skoutelis, Athanasios, Thiraios, Eleftherios, Tsiodras, Sotirios, Zaoutis, Theoklis, Zografopoulos, Dimitrios   +18 more
core   +1 more source